Additionally, recent studies suggest that the gut microbiota could be used to predict clinical response to treatment in adult patients with IBD, including anti-integrin biologics (13, 14) and treatment of pediatric IBD with anti-tumor necrosis factor alpha (anti-TNF-α) or immunomodulators (15, 16). The gene discussed is TNF; the disease is inflammatory bowel disease.